A metformin-based therapy currently in Phase 3 pivotal trials for type 2 diabetes patients with chronic kidney disease.
Anji is an asset-centric company built to rapidly pursue well-validated drug targets and improve the lives of patients everywhere. We recently completed a multinational Phase 2 proof-of-concept study for ANJ908 in chronic idiopathic constipation. Our Phase 3 program to bring ANJ900 to patients with type 2 diabetes and advanced chronic kidney disease is on track to deliver results in 2024.
Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease
Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation
Our name was inspired by the Anji Bridge (Zhaozhou Bridge), one of the oldest stone-arch bridges in the world. Anji translates to “safe crossing” and “to aid those in need.” Our biotech company bridges science and cultures to create safe and effective medicines for patients who need them most. Because building bridges is what we do.
Anji was built with a fervent desire to improve lives. Our pedigreed team blends deep drug development know-how with an unwavering resolve to get things done. Rather than focusing on what’s trendy, we focus on what works.
We’ve provided additional information and resources to untangle diseases like chronic constipation and type 2 diabetes with chronic kidney disease.